Ascendis Pharma AS (ASND)
NASDAQ · Healthcare · Biotechnology
Ascendis Pharma AS is a Healthcare company with a market capitalization of $17.10B and a trailing P/E ratio of 30.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in EUR
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $0.27 | $0.43 | -37.2% |
| Q4 2025 | February 11, 2026 | $-0.55 | $-0.24 | -129.2% |
| Q3 2025 | November 12, 2025 | $-1.00 | $-0.16 | -525.0% |
| Q2 2025 | August 7, 2025 | $-0.64 | $-1.31 | +51.1% |
| Q1 2025 | May 1, 2025 | $-1.58 | $-1.51 | -4.6% |
| Q4 2024 | February 12, 2025 | $-0.64 | $-0.93 | +31.2% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Ascendis Pharma AS's market cap?
As of June 29, 2026, Ascendis Pharma AS (ASND) has a market capitalization of $17.10B.
What is Ascendis Pharma AS's P/E ratio?
Ascendis Pharma AS trades at a trailing price-to-earnings (P/E) ratio of 30.3. Its forward P/E is 16.2.
Does Ascendis Pharma AS pay a dividend?
Ascendis Pharma AS does not currently pay a dividend.
What sector is ASND in?
Ascendis Pharma AS is in the Healthcare sector, specifically the Biotechnology industry.
What was Ascendis Pharma AS's revenue?
In its latest reported fiscal year (ending December 31, 2025), Ascendis Pharma AS reported revenue of 691.71M EUR and net income of -219.03M EUR.
Ask your own questions about ASND
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.